- PATIENT PLANS
- ABOUT US
- CONTACT US
Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.
If you missed the webinar, you can still watch the recording here.
Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar.
Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio.
Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT.
Dr. Belisario Arango covered the following topics:
Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients?
Where is the future of cancer care going?
Join Massive Bio executives and get your live demo at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Massive Bio will provide two types of demos:
• Virtual tumor board powered by Massive Bio’s proprietary pathways and sub-specialists
• Clinical trial matching and eligibility screening platform powered by Artificial Intelligence (AI) and supervised by sub-specialists
Healthcare reform is undergoing a wave of radical change and disruptive innovation, with stakeholders transitioning to value-based care delivery models to reduce costs and improve quality of care. At the same time, leveraging advanced technologies, experimenting with various business models, and developing new relationships are changing the way that medicine is practiced.
Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. However, the necessity of Massive Bio increases everyday to streamline disparate clinical and genomic information and disparate stakeholders. Precision oncology needs a translator and accelerator more than ever to be mainstream. Massive Bio put precision oncology to “work” — organizes and harmonizes disparate knowledge into clinical utility. In any case, I have summarized our key take-aways from the conference in regards to our space, digital health and AI and overall healthcare. Hope you will find it as an enjoyable read and I am always happy to have a dialogue and attack healthcare issues with like minded people together.
Editing cells’ genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies published on Monday warn — a potential game-changer for the companies developing CRISPR-based therapies.
It is a time to celebrate those who have survived, to inspire those who are recently diagnosed and a source of support for all of their families.
The immune system uses an extremely complex regulatory system to achieve the goal of effectively eradicating pathogens without causing excessive host tissue damage. A successfully coordinated immune response is dependent on secreted chemical signals (cytokines), protein–protein interactions between adjacent cells, and the activity of various enzymes that alter the microenvironment.
The American Cancer Society has released new age guidelines for adults of average risk to being colon cancer screening. The new recommended age is now 45 for both men and women.
Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians.
Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.
The short perioperative period, spanning several days pre- and postsurgery, is now believed to have a nonproportionally large impact on long-term cancer outcomes (1,2). Numerous physiological responses to the newly discovered cancer and to surgical resection trigger pro-metastatic processes that can affect minimal residual disease (MRD; single tumor cells/micrometastases).
Continued evolution in cancers gives rise to intra-tumour heterogeneity (ITH), which is a major mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. Here, we extensively characterise ITH across 2,778 cancer whole genome sequences from 36 cancer types.